Vicious Circle

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Retrieved on: 
Tuesday, October 19, 2021
ALS, IND, Visual impairment, Tissue, Death, PUFA, Cell damage, Investigational New Drug, Western world, FA, Reading, Oxidative stress, GLOBE, Patient, University, INAD, Animal, RT001, LA, Retinal pigment epithelium, Demonstration, GA, AMD, Infantile neuroaxonal dystrophy, Collection, Amyotrophic lateral sclerosis, Time, DHA, University of Pennsylvania, Vicious Circle, RATS, Disease, Drusen, LPO, Time-invariant system, Retina, Dihydroxy-E,Z,E-PUFA, Geographic atrophy, Inflammation, Central retinal artery occlusion, Degenerative disease, Dry, Injection, Â, Severe cognitive impairment, RPE, Lipid peroxidation, LOS, Program, Research, Stress (linguistics), PSP, Therapy, Vaccine, Pharmaceutical industry, Dietary supplement

LOS ALTOS, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit. Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD. Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals. The conference, which is being conducted in a virtual format, is being held October 19-21, 2021.

Key Points: 
  • Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD.
  • Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals.
  • The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
  • Study results demonstrated that animals treated with RT011 experienced decreasing levels of retinal damage with increasing tissue concentrations of RT011.